Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246394554> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4246394554 endingPage "7075" @default.
- W4246394554 startingPage "7075" @default.
- W4246394554 abstract "7075 Background: In NSCLC simultaneous or induction radiochemotherapy is superior to chemo- or radiotherapy alone. Our study proves, weather after induction chemotherapy simultaneous radiochemotherapy is superior to radiotherapy alone. Methods: Patients (pts) with inoperable NSCLC IIIA/B are included. They get 2 cycles q3w of Paclitaxel 200mg/m2 and Carboplatinum AUC 6. If the tumor is not progressive the pts are randomized to radiotherapy alone (total dose at least 60 Gy per fraction) or simultaneous chemotherapy with weekly Paclitaxel 60mg/m2 and the same radiotherapy. Primary objective is survival; secondary endpoints are time to progression, response and toxicity. Results: Inclusion ended 05/02. The last follow-up was 11/03. As planned, 303 pts are included in the trial. 275 pts finished induction-therapy. 219 pts could be randomized: radiotherapy 115 pts, simultaneous radiochemotherapy 104 pts. Median survival is higher in the simultaneous arm: 18.67 months (95%CI 14.05–23.29) versus 14.1 months (95%CI 11.64–16.56). Progression free survival is statistically superior (log rank: p=0.0003) in the simultaneous arm: median 11.43 months (95%CI 7.88–14.98) versus 5.57 months (95%CI 3.88–7.25). In the simultaneous arm there are also statistically less recurrences (Pearson Chi-Square: p<0.001): 62.1% vs. 83.8%. The reduction on recurrences can be seen in local as in distant relapses. Toxicities are not statistically different. Conclusions: The combination of induction chemotherapy and then simultaneous radiochemotherapy with weekly Paclitaxel is superior to induction alone regarding progression-free survival, without increased toxicities. Also the survival seems to be better (not yet statistically significant). Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Germany Bristol-Myers Squibb" @default.
- W4246394554 created "2022-05-12" @default.
- W4246394554 creator A5003455344 @default.
- W4246394554 creator A5003670561 @default.
- W4246394554 creator A5021699038 @default.
- W4246394554 creator A5028446464 @default.
- W4246394554 creator A5038344266 @default.
- W4246394554 creator A5055767605 @default.
- W4246394554 creator A5055932610 @default.
- W4246394554 date "2004-07-15" @default.
- W4246394554 modified "2023-09-25" @default.
- W4246394554 title "Induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): Update of CT/RT 99/97" @default.
- W4246394554 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.7075" @default.
- W4246394554 hasPublicationYear "2004" @default.
- W4246394554 type Work @default.
- W4246394554 citedByCount "1" @default.
- W4246394554 crossrefType "journal-article" @default.
- W4246394554 hasAuthorship W4246394554A5003455344 @default.
- W4246394554 hasAuthorship W4246394554A5003670561 @default.
- W4246394554 hasAuthorship W4246394554A5021699038 @default.
- W4246394554 hasAuthorship W4246394554A5028446464 @default.
- W4246394554 hasAuthorship W4246394554A5038344266 @default.
- W4246394554 hasAuthorship W4246394554A5055767605 @default.
- W4246394554 hasAuthorship W4246394554A5055932610 @default.
- W4246394554 hasConcept C126322002 @default.
- W4246394554 hasConcept C141071460 @default.
- W4246394554 hasConcept C143998085 @default.
- W4246394554 hasConcept C146357865 @default.
- W4246394554 hasConcept C151730666 @default.
- W4246394554 hasConcept C168563851 @default.
- W4246394554 hasConcept C203092338 @default.
- W4246394554 hasConcept C2776611710 @default.
- W4246394554 hasConcept C2776694085 @default.
- W4246394554 hasConcept C2777292972 @default.
- W4246394554 hasConcept C509974204 @default.
- W4246394554 hasConcept C71924100 @default.
- W4246394554 hasConcept C86803240 @default.
- W4246394554 hasConceptScore W4246394554C126322002 @default.
- W4246394554 hasConceptScore W4246394554C141071460 @default.
- W4246394554 hasConceptScore W4246394554C143998085 @default.
- W4246394554 hasConceptScore W4246394554C146357865 @default.
- W4246394554 hasConceptScore W4246394554C151730666 @default.
- W4246394554 hasConceptScore W4246394554C168563851 @default.
- W4246394554 hasConceptScore W4246394554C203092338 @default.
- W4246394554 hasConceptScore W4246394554C2776611710 @default.
- W4246394554 hasConceptScore W4246394554C2776694085 @default.
- W4246394554 hasConceptScore W4246394554C2777292972 @default.
- W4246394554 hasConceptScore W4246394554C509974204 @default.
- W4246394554 hasConceptScore W4246394554C71924100 @default.
- W4246394554 hasConceptScore W4246394554C86803240 @default.
- W4246394554 hasIssue "14_suppl" @default.
- W4246394554 hasLocation W42463945541 @default.
- W4246394554 hasOpenAccess W4246394554 @default.
- W4246394554 hasPrimaryLocation W42463945541 @default.
- W4246394554 hasRelatedWork W1991954518 @default.
- W4246394554 hasRelatedWork W2053778437 @default.
- W4246394554 hasRelatedWork W2295588572 @default.
- W4246394554 hasRelatedWork W2355670240 @default.
- W4246394554 hasRelatedWork W2362144381 @default.
- W4246394554 hasRelatedWork W2376593068 @default.
- W4246394554 hasRelatedWork W2392262560 @default.
- W4246394554 hasRelatedWork W2597582218 @default.
- W4246394554 hasRelatedWork W2997709950 @default.
- W4246394554 hasRelatedWork W84951532 @default.
- W4246394554 hasVolume "22" @default.
- W4246394554 isParatext "false" @default.
- W4246394554 isRetracted "false" @default.
- W4246394554 workType "article" @default.